Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
In this report we evaluated the clinical performance of APOE genotyping and three protein biomarkers (total tau, beta-amyloid(1-42), and tau phosphorylated at threonine 181) in a prospective multicenter study using the INNO-BIA AlzBio3 assay applied on Luminex platform. Concentration of biomarkers of Alzheimer's disease in cerebrospinal fluid (CSF) was measured with multiplexing technology (n=223), and compared to the results of ELISA assays in patients with early dementias or mild cognitive impairment (MCI) collected at 12 gerontopsychiatric university departments, and APOE genotyping was performed. Concentrations of Abeta(1-42) were statistically significantly lower in MCI-AD subjects compared to MCI-O, and significantly lower in D-AD patients compared to MCI-O. P-tau(181P) concentrations were significantly higher in MCI-AD patients compared to MCI-O, and significantly higher in D-AD patients compared to MCI-O. The total tau concentrations in MCI-AD patients were significantly higher compared to MCI-O, and higher in D-AD compared to MCI-O, moreover, the concentration of total tau was significantly higher in D-AD compared to MCI-AD patients. For the differential diagnosis between D-AD and D-O, the optimal cutoff concentration of Abeta(1-42) was 197.7 pg/mL, and that for P-tau(181P) was 47.9 pg/mL. These cutoff values were also applied to discriminate between MCI-AD and MCI-O subjects. Simultaneous measurement of the biomarkers significantly improves management of the samples and quality control of the assays' performance.
Lewczuk
Piotr
P
Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.
Kornhuber
Johannes
J
Vanderstichele
Hugo
H
Vanmechelen
Eugeen
E
Esselmann
Hermann
H
Bibl
Mirko
M
Wolf
Stefanie
S
Otto
Markus
M
Reulbach
Udo
U
Kölsch
Heike
H
Jessen
Frank
F
Schröder
Johannes
J
Schönknecht
Peter
P
Hampel
Harald
H
Peters
Oliver
O
Weimer
Erik
E
Perneczky
Robert
R
Jahn
Holger
H
Luckhaus
Christian
C
Lamla
Ulrich
U
Supprian
Tillmann
T
Maler
Juan Manuel
JM
Wiltfang
Jens
J
D000368:Aged; D000465:Algorithms; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000453:epidemiology*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000453:epidemiology*; D015897:Comorbidity; D003704:Dementia / Q000134:cerebrospinal fluid*; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins